Flow Cytometry in Oncology and Immunology Market Report 2026

The flow cytometry in oncology and immunology market size has grown rapidly in recent years. It will grow from $2.32 billion in 2025 to $2.56 billion in 2026 at a compound annual growth rate (CAGR) of 10.2%. The growth in the historic period can be attributed to growth in cancer research funding, expansion of immunotherapy development, availability of advanced cytometry platforms, increased clinical trial activity, rising need for immune monitoring.

The flow cytometry in oncology and immunology market size is expected to see rapid growth in the next few years. It will grow to $3.82 billion in 2030 at a compound annual growth rate (CAGR) of 10.5%. The growth in the forecast period can be attributed to demand for personalized oncology diagnostics, integration with genomic data, growth in immuno-oncology therapies, expansion of clinical research pipelines, advances in multiplex analysis. Major trends in the forecast period include rising use in cancer biomarker identification, increased adoption in immune cell profiling, expansion of minimal residual disease detection, growing application in translational research, integration of high-dimensional data analysis.

The rising prevalence of HIV/AIDS is expected to drive growth in the flow cytometry market for oncology and immunology. HIV is a virus that attacks the immune system, specifically targeting CD4 cells, which are white blood cells essential for fighting infections. If left untreated, HIV can progress to AIDS, the final stage of infection. Flow cytometry is widely used in HIV/AIDS research and clinical practice to analyze and characterize cells, particularly immune cells, based on their physical and chemical properties. It can also identify latently infected T cells that carry the HIV genome without actively producing the virus. For example, in July 2024, UNAIDS, a Switzerland-based UN program, reported that in 2023 approximately 39.9 million people were living with HIV globally, up from 39.0 million in 2022. Therefore, the increasing prevalence of HIV/AIDS is boosting the flow cytometry market in oncology and immunology.

Key companies in the flow cytometry market for oncology and immunology are focusing on innovations such as spectral flow cytometry to maintain a competitive edge. Spectral flow cytometry captures the full emission spectrum of each fluorescent marker rather than detecting fixed, narrow-band signals, allowing high-parameter, multiparametric cell analysis. For instance, in May 2024, Agilent Technologies, a US-based life sciences company, launched the NovoCyte Opteon spectral flow cytometer, featuring three to five lasers, up to 73 detectors, and the ability to analyze more than 40 markers in a single run. This system enhances deep immunophenotyping capabilities in oncology and immunology research, offering advantages like flexible panel design, reduced spectral overlap, and improved signal resolution, though it requires more complex data unmixing, which may increase analysis time.

In February 2023, Cytek Biosciences, a US-based provider of high-parameter flow cytometry instruments, reagents, software, and cell analysis solutions, acquired Luminex Corporation’s Flow Cytometry & Imaging (FCI) business unit for an undisclosed amount. This acquisition allowed Cytek to expand its portfolio to include imaging flow cytometry and menu-driven, application-specific cytometry, offering a more comprehensive cell analysis platform. Luminex Corporation, a US-based company, provides conventional and image-based flow cytometry instruments along with reagents and related services.

Major companies operating in the flow cytometry in oncology and immunology market are Thermo Fisher Scientific Inc., Danaher Corporation, Merck KGaA, Becton Dickinson and Company, Agilent Technologies Inc., Sartorius AG, Beckman Coulter Inc., Bio-Rad Laboratories Inc., Sysmex Partec GmbH, Miltenyi Biotec, Luminex Corporation, Q2 Solutions LLC, BioLegend Inc., Cytek Biosciences Inc., Cell Signaling Technology Inc., Standard BioTools Inc., Sony Biotechnology Inc., NanoCellect Biomedical Inc., Nexcelom Bioscience LLC, CytoReason.

North America was the largest region in the flow cytometry in oncology and immunology market in 2025. The regions covered in the flow cytometry in oncology and immunology market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the flow cytometry in oncology and immunology market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have influenced the flow cytometry in oncology and immunology market by raising prices for imported antibodies, fluorescent probes, cytometers, and data-analysis software. Diagnostic laboratories and pharmaceutical companies in Asia-Pacific and Europe are most impacted due to global sourcing of advanced research tools. These higher costs can delay cancer and immune-profile testing. However, tariffs are driving domestic reagent production and platform development, strengthening long-term research capacity.

The flow cytometry in oncology and immunology market research report is one of a series of new reports that provides flow cytometry in oncology and immunology market statistics, including flow cytometry in oncology and immunology industry global market size, regional shares, competitors with a flow cytometry in oncology and immunology market share, detailed flow cytometry in oncology and immunology market segments, market trends and opportunities, and any further data you may need to thrive in the flow cytometry in oncology and immunology industry. This flow cytometry in oncology and immunology market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Flow cytometry is a powerful analytical technique used in oncology and immunology to measure and assess the physical and chemical properties of cells or particles as they move through a fluid stream and pass a laser beam. This technology allows for the simultaneous measurement of multiple cellular parameters, including cell size, granularity, and the expression of surface and intracellular markers, enabling detailed analysis of cell populations and their functions in both health and disease.

The main categories of flow cytometry in oncology and immunology are immunology and oncology. Immunology is a branch of biomedical science focused on the study of the immune system and its responses to foreign substances, known as antigens. In these fields, flow cytometry employs various technologies, such as cell-based and bead-based flow cytometry, for applications including translational and clinical research. The end users of these technologies include hospitals, diagnostic laboratories, reference laboratories, pharmaceutical and biotechnology companies, academic research institutes, contract research organizations, and others.

The flow cytometry in oncology and immunology market includes revenues earned by entities by providing services such as cell-based assay services, drug development services, and minimal residual disease (MRD) monitoring. The market value includes the value of related goods sold by the service provider or included within the service offering. The flow cytometry in oncology and immunology market also consists of sales of products flow cytometers, fluorescence-activated cell sorters (FACS), monoclonal antibodies, and fluorochromes. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.